Can't get Aimovig? Learn about FDA-approved alternatives like Ajovy, Emgality, Vyepti, and Qulipta for migraine prevention in 2026.
If you've been prescribed Aimovig (Erenumab-aooe) but can't fill your prescription — whether due to pharmacy availability, insurance denials, or cost — you're probably wondering what else is out there. The good news is that Aimovig isn't the only game in town.
Since Aimovig was first approved in 2018, several other medications in the same class have come to market. They all target the CGRP pathway, and for many patients, switching between them is a viable option. Let's walk through what Aimovig is, how it works, and what alternatives are worth discussing with your doctor.
Aimovig is a monoclonal antibody that blocks the calcitonin gene-related peptide (CGRP) receptor. CGRP is a protein that plays a central role in migraine — it triggers inflammation, dilates blood vessels in the brain, and transmits pain signals. When CGRP binds to its receptor, it can set off the cascade that leads to a migraine attack.
Aimovig works by sitting on that receptor and preventing CGRP from binding to it. Think of it as a bouncer at the door — CGRP shows up, but Aimovig won't let it in. This makes Aimovig fundamentally different from the other CGRP inhibitors, which target the CGRP protein itself rather than the receptor.
It's given as a once-monthly subcutaneous injection (70 mg or 140 mg) using a prefilled autoinjector. For a deeper dive, check out how Aimovig works: mechanism of action explained.
There are several reasons you might be looking for an Aimovig alternative:
How it works: Unlike Aimovig, which blocks the CGRP receptor, Ajovy targets the CGRP protein itself. By binding directly to CGRP, it prevents the protein from activating its receptor and triggering migraine.
How it's given: Subcutaneous injection. You can choose between 225 mg once monthly or 675 mg once quarterly (three injections in one day, every three months). The quarterly option is appealing for patients who don't want a monthly shot.
Key differences from Aimovig: Different mechanism (targets CGRP ligand vs. receptor), offers a quarterly dosing option, and may have a different side effect profile. Constipation is less commonly reported with Ajovy compared to Aimovig.
Cost: Similar to Aimovig at around $700–$1,000/month without insurance. Teva offers a copay savings program for eligible commercially insured patients.
How it works: Like Ajovy, Emgality targets the CGRP protein directly rather than the receptor. It binds to CGRP and prevents it from triggering migraine pathways.
How it's given: Subcutaneous injection. 240 mg loading dose (two 120 mg injections) on the first day, then 120 mg once monthly. Emgality is also FDA-approved for episodic cluster headache — the only CGRP inhibitor with this indication.
Key differences from Aimovig: Loading dose allows faster onset of action. Approved for both migraine prevention and cluster headache. Made by Eli Lilly.
Cost: Around $700–$950/month without insurance. Eli Lilly offers savings programs through LillyDirect.
How it works: Vyepti also targets the CGRP protein. It's structurally similar in approach to Ajovy and Emgality.
How it's given: IV infusion every 3 months (100 mg or 300 mg). This is the only CGRP inhibitor given intravenously. Infusions are administered in a healthcare setting and take about 30 minutes.
Key differences from Aimovig: No self-injection required — it's given by IV in a clinic. Quarterly dosing means only 4 treatments per year. Onset can be faster since the medication goes directly into the bloodstream. However, it requires an office visit for each infusion.
Cost: The list price is higher than the injectable options (around $1,500–$2,000 per infusion), but insurance coverage and copay programs can bring the out-of-pocket cost down significantly.
How it works: Qulipta is an oral CGRP receptor antagonist (a "gepant"). Like Aimovig, it blocks the CGRP receptor — but it's a small molecule taken as a pill, not an antibody given by injection.
How it's given: Daily oral tablet — available in 10 mg, 30 mg, and 60 mg doses. This is the only daily oral CGRP preventive medication.
Key differences from Aimovig: No injections. Daily dosing (vs. monthly). Faster washout if you experience side effects (the drug clears your system in days, not weeks like antibodies). However, daily adherence is required.
Cost: Around $900–$1,100/month without insurance. AbbVie offers a savings program for eligible patients.
If CGRP inhibitors as a class aren't working for you or aren't accessible, there are other FDA-approved preventive migraine treatments:
These medications work through different mechanisms and may be appropriate if CGRP inhibitors are unavailable or ineffective.
Not being able to fill your Aimovig prescription is stressful — but it doesn't mean you're out of options. Several CGRP inhibitors offer similar benefits, and your doctor can help you choose the one that best fits your situation, insurance coverage, and preferences.
Before switching, try using Medfinder to see if Aimovig is available at another pharmacy near you. And if cost is the issue, check out our guide to saving money on Aimovig in 2026.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
